# Atomoxetine

## apo-ATOMOXETINE 25mg

| TAH Drug Code      | [OATM25](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OATM25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | 6 years or older, up to 70 kg: Acute treatment: Initial, approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily, as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day, whichever is less 6 years or older, greater than 70 kg: Acute treatment: Initial, 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; MAX 100 mg daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma, current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg, 15 to 20 mm Hg) or heart rate (eg, 20 beats per minute)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common Cardiovascular: Increased heart rate (Adult, 10.2% to 22.4%; pediatric, 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult, 2%; pediatric, 3% ) Gastrointestinal: Abdominal pain (Adult, 7%; pediatric, 18% ), Constipation (Adult, 8%; pediatric, 1% to 2% ), Decrease in appetite (Adult, 16%; pediatric, 16% ), Nausea (Adult, 26%; pediatric, 10% ), Vomiting (Adult, 4%; pediatric, 11% ), Xerostomia (Adult, 20% ) Neurologic: Dizziness (Adult, 8%; pediatric, 5% ), Headache (Pediatric, 19% ), Insomnia (Adult, 15%; pediatric, at least 2% ), Somnolence (Adult, 8%; pediatric, 11% ) Renal: Delay when starting to pass urine (Adult, 6% ) Reproductive: Dysmenorrhea (Adult, 3% ), Erectile dysfunction (Adult, 8% ) Other: Fatigue (Adult, 10%; pediatric, 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult, 4.8% to 12.6%; pediatric, 9.3% to 21.5% ), Increased systolic arterial pressure (Adult, 4.2% to 12.4%; pediatric, 4.9% to 12.5% ), Myocardial infarction, Sudden cardiac death, Tachycardia (Adult, 1.5%; pediatric, 0.3% ) Hepatic: Injury of liver (Severe), Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior, Hostile behavior, Mania, Psychotic disorder, Suicidal thoughts (Pediatric, 0.4% ) Reproductive: Priapism |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## apo-Atomoxetine 18mg

| TAH Drug Code      | [OATMX](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OATMX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | Acute treatment:6 years or older, up to 70 kg: Acute treatment: Initial, approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily, as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; maximum 1.4 mg/kg daily or 100 mg/day, whichever is less Acute treatment: 6 years or older, greater than 70 kg: Acute treatment: Initial, 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; maximum 100 mg daily. Maintenance / continuous treatment: 1.2～1.8 mg/ kg/ day.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma, current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg, 15 to 20 mm Hg) or heart rate (eg, 20 beats per minute)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common Cardiovascular: Increased heart rate (Adult, 10.2% to 22.4%; pediatric, 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult, 2%; pediatric, 3% ) Gastrointestinal: Abdominal pain (Adult, 7%; pediatric, 18% ), Constipation (Adult, 8%; pediatric, 1% to 2% ), Decrease in appetite (Adult, 16%; pediatric, 16% ), Nausea (Adult, 26%; pediatric, 10% ), Vomiting (Adult, 4%; pediatric, 11% ), Xerostomia (Adult, 20% ) Neurologic: Dizziness (Adult, 8%; pediatric, 5% ), Headache (Pediatric, 19% ), Insomnia (Adult, 15%; pediatric, at least 2% ), Somnolence (Adult, 8%; pediatric, 11% ) Renal: Delay when starting to pass urine (Adult, 6% ) Reproductive: Dysmenorrhea (Adult, 3% ), Erectile dysfunction (Adult, 8% ) Other: Fatigue (Adult, 10%; pediatric, 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult, 4.8% to 12.6%; pediatric, 9.3% to 21.5% ), Increased systolic arterial pressure (Adult, 4.2% to 12.4%; pediatric, 4.9% to 12.5% ), Myocardial infarction, Sudden cardiac death, Tachycardia (Adult, 1.5%; pediatric, 0.3% ) Hepatic: Injury of liver (Severe), Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior, Hostile behavior, Mania, Psychotic disorder, Suicidal thoughts (Pediatric, 0.4% ) Reproductive: Priapism |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## Strattera 10mg

| TAH Drug Code      | [OSTR1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSTR1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Adult, adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg, whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult, adolescent & children>70 kg maximum dose is 100 mg total daily .                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | with a MAOI or within 2 weeks after discontinuing a MAOI, narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence. Endocrine metabolic: Weight loss (pediatrics, 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults, 7%; pediatrics, 17% to 18% ), Constipation (adults, 9%; pediatric, 1% to 2%), Decrease in appetite (adult, 11%; pediatrics, 16% ,), Nausea (adults, 21%; pediatrics, 7% to 13% ), Vomiting (adults, 3%; pediatrics, 11%), Xerostomia (adults, 21% ) Neurologic: Headache (pediatrics, 19% ), Insomnia (adults, 16%; pediatrics, at least 2%; ), Somnolence (adult, 4%; pediatrics, 11% ) Renal: Delay when starting to pass urine (adults, 5.6% ), Urinary retention (adults, 1.7% ) Reproductive: Dysmenorrhea (adults, 6% ), Erectile dysfunction (adults, 9% ) Other: Menopausal flushing (adults, 8% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## STRATTERA 40MG

| TAH Drug Code      | [OSTR4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSTR4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of attention-deficit/hyperactivity disorder (ADHD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Adult, adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg, whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult, adolescent & children>70 kg maximum dose is 100 mg total daily .                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | with a MAOI or within 2 weeks after discontinuing a MAOI, narrow-Angle Glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence. Endocrine metabolic: Weight loss (pediatrics, 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults, 7%; pediatrics, 17% to 18% ), Constipation (adults, 9%; pediatric, 1% to 2%), Decrease in appetite (adult, 11%; pediatrics, 16% ,), Nausea (adults, 21%; pediatrics, 7% to 13% ), Vomiting (adults, 3%; pediatrics, 11%), Xerostomia (adults, 21% ) Neurologic: Headache (pediatrics, 19% ), Insomnia (adults, 16%; pediatrics, at least 2%; ), Somnolence (adult, 4%; pediatrics, 11% ) Renal: Delay when starting to pass urine (adults, 5.6% ), Urinary retention (adults, 1.7% ) Reproductive: Dysmenorrhea (adults, 6% ), Erectile dysfunction (adults, 9% ) Other: Menopausal flushing (adults, 8% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

